JP2010523726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523726A5 JP2010523726A5 JP2010503393A JP2010503393A JP2010523726A5 JP 2010523726 A5 JP2010523726 A5 JP 2010523726A5 JP 2010503393 A JP2010503393 A JP 2010503393A JP 2010503393 A JP2010503393 A JP 2010503393A JP 2010523726 A5 JP2010523726 A5 JP 2010523726A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- disease
- drug
- treatment
- addiction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000011117 substance-related disease Diseases 0.000 claims description 26
- 208000007848 Alcoholism Diseases 0.000 claims description 17
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 15
- 206010013663 drug dependence Diseases 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 206010013654 Drug abuse Diseases 0.000 claims description 12
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 12
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000020629 overactive bladder Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 201000007930 alcohol dependence Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000018526 Narcotic-Related disease Diseases 0.000 claims description 8
- 108010025083 TRPV1 receptor Proteins 0.000 claims description 8
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 8
- 201000005040 opiate dependence Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 206010059866 Drug resistance Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 206010046543 Urinary incontinence Diseases 0.000 claims description 6
- 206010001584 alcohol abuse Diseases 0.000 claims description 6
- 208000025746 alcohol use disease Diseases 0.000 claims description 6
- 210000001508 eye Anatomy 0.000 claims description 6
- 210000000936 intestine Anatomy 0.000 claims description 6
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 210000002850 nasal mucosa Anatomy 0.000 claims description 6
- 229940005483 opioid analgesics Drugs 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 claims description 6
- 210000003932 urinary bladder Anatomy 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000007278 cognition impairment Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- RLWGDRLXZSLGHV-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[(4-tert-butylphenyl)methyl]urea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 RLWGDRLXZSLGHV-UHFFFAOYSA-N 0.000 claims description 4
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 206010006895 Cachexia Diseases 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000009889 Herpes Simplex Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 208000004880 Polyuria Diseases 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 4
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 claims description 4
- 108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 claims description 4
- 206010047642 Vitiligo Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 229960002504 capsaicin Drugs 0.000 claims description 4
- 235000017663 capsaicin Nutrition 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 230000035619 diuresis Effects 0.000 claims description 4
- 208000000718 duodenal ulcer Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 230000029142 excretion Effects 0.000 claims description 4
- 201000005917 gastric ulcer Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 230000037023 motor activity Effects 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 206010015946 Eye irritation Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 230000036626 alertness Effects 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 210000000748 cardiovascular system Anatomy 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 231100000013 eye irritation Toxicity 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 230000007794 irritation Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 208000037804 stenosis Diseases 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010029333 Neurosis Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 238000002690 local anesthesia Methods 0.000 claims 2
- 208000015238 neurotic disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010006487 Bronchostenosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 description 11
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 208000009935 visceral pain Diseases 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 2
- 229940073454 resiniferatoxin Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 206010024421 Libido increased Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007018151.7 | 2007-04-16 | ||
| DE102007018151A DE102007018151A1 (de) | 2007-04-16 | 2007-04-16 | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| PCT/EP2008/002994 WO2008125337A2 (de) | 2007-04-16 | 2008-04-15 | Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523726A JP2010523726A (ja) | 2010-07-15 |
| JP2010523726A5 true JP2010523726A5 (enExample) | 2013-12-12 |
| JP5557734B2 JP5557734B2 (ja) | 2014-07-23 |
Family
ID=39540731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503393A Expired - Fee Related JP5557734B2 (ja) | 2007-04-16 | 2008-04-15 | 新規バニロイド受容体リガンド及び医薬の製造におけるその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8642775B2 (enExample) |
| EP (1) | EP2146962A2 (enExample) |
| JP (1) | JP5557734B2 (enExample) |
| KR (1) | KR101497357B1 (enExample) |
| CN (1) | CN101687799B (enExample) |
| BR (1) | BRPI0810031A2 (enExample) |
| CA (1) | CA2683910A1 (enExample) |
| CO (1) | CO6220938A2 (enExample) |
| DE (1) | DE102007018151A1 (enExample) |
| EC (1) | ECSP099693A (enExample) |
| IL (1) | IL201506A0 (enExample) |
| MX (1) | MX2009011139A (enExample) |
| NZ (2) | NZ580381A (enExample) |
| RU (1) | RU2487120C2 (enExample) |
| WO (1) | WO2008125337A2 (enExample) |
| ZA (1) | ZA200907096B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090275515A1 (en) * | 2006-10-18 | 2009-11-05 | Yuntae Kim | 2-hydroxy-2-phenylthiophenylpropionamides as androgen receptor modulators |
| WO2008110351A2 (en) * | 2007-03-15 | 2008-09-18 | Dompe' Pha.R.Ma S.P.A. | Use of (r) and (s)-2-aryl-propionic acid derivatives as antiseptic agents |
| DE102007018151A1 (de) * | 2007-04-16 | 2008-10-23 | Günenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| EP2709609B1 (en) * | 2011-05-17 | 2017-10-04 | Shionogi & Co., Ltd. | Heterocyclic compounds |
| JP2013014534A (ja) * | 2011-07-04 | 2013-01-24 | Daicel Corp | ベンゾイルギ酸化合物、及びその製造方法 |
| WO2013013817A1 (en) | 2011-07-26 | 2013-01-31 | Grünenthal GmbH | Substituted heterocyclic aza derivatives |
| MX2014000963A (es) | 2011-07-26 | 2014-03-27 | Gruenenthal Gmbh | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. |
| HK1202116A1 (en) * | 2011-11-09 | 2015-09-18 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands |
| ES2823577T3 (es) * | 2011-11-09 | 2021-05-07 | Medifron Dbt Inc | Derivados de urea basados en pirazolilo sustituido como ligandos del receptor vainilloide |
| CA3106470A1 (en) | 2018-07-17 | 2020-01-23 | Nippon Chemiphar Co., Ltd. | T-type calcium channel blocker |
| EP3950059A4 (en) | 2019-03-29 | 2023-01-11 | Nippon Chemiphar Co., Ltd. | USE OF A T-TYPE CALCIUM CHANNEL BLOCKER TO TREAT PRURITUS |
| RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
| CN115417809A (zh) * | 2022-09-05 | 2022-12-02 | 天津药明康德新药开发有限公司 | 一种4,4-二吡咯-2,2-联吡啶的制备方法 |
| CN120860208A (zh) * | 2024-04-30 | 2025-10-31 | 中国人民解放军军事科学院军事医学研究院 | 刺激trpv1+感觉神经预防和治疗疾病 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1209016C (zh) * | 1999-08-18 | 2005-07-06 | 阿方蒂农科有限公司 | 杀真菌剂 |
| GB9919588D0 (en) * | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| DE60120421T2 (de) | 2000-08-21 | 2006-12-28 | Pacific Corp. | Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten |
| TWI239942B (en) * | 2001-06-11 | 2005-09-21 | Dainippon Pharmaceutical Co | N-arylphenylacetamide derivative and pharmaceutical composition containing the same |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| JP2005527517A (ja) * | 2002-03-14 | 2005-09-15 | ビーエーエスエフ アクチェンゲゼルシャフト | Ｚ置換アクリルアミド、それらの調製、およびそれらを含む組成物 |
| TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
| US6933311B2 (en) | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| EP1628661A2 (en) | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| KR100707123B1 (ko) | 2003-07-02 | 2007-04-16 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물 |
| ES2289691T3 (es) | 2004-01-22 | 2008-02-01 | Pfizer, Inc. | Derivados de sulfonamida para el tratamiento de enfermedades. |
| US20050165015A1 (en) | 2004-01-23 | 2005-07-28 | Ncube Mghele V. | Vanilloid receptor ligands and their use in treatments |
| EP1764095A1 (en) | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| KR101347102B1 (ko) * | 2005-10-19 | 2014-01-03 | 그뤼넨탈 게엠베하 | 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도 |
| DE102007018151A1 (de) * | 2007-04-16 | 2008-10-23 | Günenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
-
2007
- 2007-04-16 DE DE102007018151A patent/DE102007018151A1/de not_active Withdrawn
-
2008
- 2008-04-15 JP JP2010503393A patent/JP5557734B2/ja not_active Expired - Fee Related
- 2008-04-15 NZ NZ580381A patent/NZ580381A/en not_active IP Right Cessation
- 2008-04-15 KR KR1020097023888A patent/KR101497357B1/ko not_active Expired - Fee Related
- 2008-04-15 EP EP08735252A patent/EP2146962A2/de not_active Withdrawn
- 2008-04-15 NZ NZ599254A patent/NZ599254A/xx not_active IP Right Cessation
- 2008-04-15 RU RU2009142024/04A patent/RU2487120C2/ru not_active IP Right Cessation
- 2008-04-15 BR BRPI0810031-4A2A patent/BRPI0810031A2/pt not_active IP Right Cessation
- 2008-04-15 CN CN200880020516.5A patent/CN101687799B/zh not_active Expired - Fee Related
- 2008-04-15 MX MX2009011139A patent/MX2009011139A/es active IP Right Grant
- 2008-04-15 WO PCT/EP2008/002994 patent/WO2008125337A2/de not_active Ceased
- 2008-04-15 CA CA002683910A patent/CA2683910A1/en not_active Abandoned
- 2008-04-15 US US12/103,198 patent/US8642775B2/en not_active Expired - Fee Related
-
2009
- 2009-10-12 ZA ZA2009/07096A patent/ZA200907096B/en unknown
- 2009-10-14 IL IL201506A patent/IL201506A0/en unknown
- 2009-10-16 CO CO09115659A patent/CO6220938A2/es active IP Right Grant
- 2009-10-16 EC EC2009009693A patent/ECSP099693A/es unknown
-
2011
- 2011-03-31 US US13/077,452 patent/US8791268B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526061A5 (enExample) | ||
| KR101931896B1 (ko) | 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법 | |
| WO2021202720A1 (en) | Use of triterpenoid nrf2 inhibitors | |
| NO20075354L (no) | Forbindelser, isomerer og farmasoytiske akseptable salter derav, som vanilloidreseptorantagoniser, og farmasoytiske preparater inneholdende slike | |
| JP2016053060A (ja) | 疾患の治療のための二重機構阻害剤 | |
| MX2010001236A (es) | Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1). | |
| JP2009500427A5 (enExample) | ||
| MX2007014879A (es) | (s)-n-metilnaltrexona, procedimiento para su sintesis y su uso farmaceutico. | |
| JP2017524005A5 (enExample) | ||
| CA2719749A1 (en) | Methods for treating disorders using nmda nr2b-subtype selective antagonist | |
| CA2669915A1 (en) | Substituted bicyclocarboxyamide compounds | |
| JP2013523893A5 (enExample) | ||
| TW201114418A (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
| JP7167236B2 (ja) | せん妄の予防または治療剤 | |
| KR102221928B1 (ko) | 아미노사이클로부탄 유도체들, 이들을 제조하는 방법 및 약물들로서 그들의 용도 | |
| WO2009096701A3 (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
| WO2015070713A1 (zh) | 柠檬苦素肟醚衍生物、其制法以及医药用途 | |
| EP4531833A2 (en) | Carbamoyl phenylalaninol compounds as taar1 agonists | |
| JP2008540592A5 (ja) | 置換されたスピロ化合物及び鎮痛剤の製造へのその使用 | |
| RU2006117627A (ru) | Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений | |
| US8455549B2 (en) | Carbonylamino derivatives useful for the treatment of certain inflammatory disorders | |
| JP2008542414A5 (enExample) | ||
| JP2008538366A5 (enExample) | ||
| WO2008112238A1 (en) | 2, 8-dimethyl-5- [2- (6-methylpyridin-3-yl) -ethyl] -2,3,4, 5-tetrahydro- ih- pyrido [4, 3 -b] indole dihydrochloride (dimebon) for the treatment of chronic pain | |
| US20180118687A1 (en) | Cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof |